focus -WSS

focus

author：focus 2025-09-30 15:22:34 - browse：38289

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Adam's Biotech Scorecard: Do Sarepta's exon

knowledge

WSS

15 die by electrocution after transformer explodes in northern India

Akili, maker of video game for ADHD, to be acquired for 34 million

Health insurers say they are turning to AI to cut costs, improve care

Antibiotic resistance nearly killed me, so I'm raising awareness of it

UK homeowners get some respite as inflation falls by more than anticipated to a 15

David Sabatini, ex

Wikipedia

focus

knowledge

Continuity nursing helped my family in our darkest PICU moments

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

What does generative AI mean for health care? We asked experts

Health insurers say they are turning to AI to cut costs, improve care

Medicare details structure of new drug price negotiation program

Stigma and the return of syphilis

In age of alternative facts, a scholarly course on calling out crap

More hospitals are billing patients as online messages surge

Psychedelics group wrestles with new pharma identity

Manchin plays down potential 3rd

focus

iTeos Therapeutics debuts first data on TIGIT

A strong 6.5

Startling documents reveal new facets of Sacklers' opioid empire

A look at other Americans who have crossed into North Korea over the years

Addiction doctors spar with methadone clinics over legislation

Dark money group runs ads on China biotech bill

knowledge

hotspot

focus

entertainment